As obesity-associated chronic inflammation contributes to insulin resistance, JAZF1 has been identified as a potential target for therapeutic strategies for T2D due to its role in mitigating insulin resistance [60]. Here, JAZF1 is linked to obesity due to melanocortin 4 receptor deficiency.